HBV感染患者IP-10表达及其预测HBsAg水平降低的能力。

StephenW

Mol Cells. 2017 Jun 14. doi: 10.14348/molcells.2017.0051. [Epub ahead of print]
IP-10 Expression in Patients with Chronic HBV Infection and Its Ability to Predict the Decrease in HBsAg Levels after Treatment with Entecavir.Zhao K1,2, Yang T3,2, Sun M4, Zhang W4, An Y4, Chen G4, Jin L3, Shang Q4, Song W1.
Author information
1Institute of Immunology, Taishan Medical University, Tai'an 271000, China.2These authors contributed equally to this work.3Research Centre for Biological Therapy, Institute of Translational Hepatology, Beijing 302 Hospital, Beijing 100039, China.4>Department of Liver Disease, the 88th Hospital of PLA, Tai'an 271000, China.

AbstractInterferon-γ-inducible protein 10 (IP-10), also known as chemokine C-X-C motif ligand (CXCL) 10, is closely associated with antiviral immunity and the progression of chronic hepatitis B (CHB). However, the value of baseline serological and histological IP-10 expression levels in predicting the efficacy of the antiviral response to nucleoside/nucleotide analogues (NAs) is still unknown. In our research, intrahepatic and peripheral IP-10 expression levels were systemically examined before and after treatment with entecavir (ETV). Baseline serological and histological IP-10 expression levels were significantly increased in patients with CHB, particularly in patients with higher degrees of liver inflammation and liver fibrosis. Moreover, higher baseline intrahepatic IP-10 levels indicated better prognoses in patients with CHB after entecavir therapy. The baseline IP-10 level was also positively associated with several clinical parameters, including baseline levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), hepatitis B virus (HBV) DNA, and hepatitis B surface antigen (HBsAg), and with the decrease in HBsAg levels after treatment. In addition, monocyte-derived IP-10 was expressed at higher levels in patients with CHB than in patients with liver cirrhosis (LC) and healthy controls (HC). According to the results of our in vitro experiments, IP-10 directly promoted hepatocyte apoptosis. Based on these findings, baseline serological and histological IP-10 levels might predict CHB severity and the decrease in HBsAg levels after entecavir therapy.


PMID:28614914DOI:10.14348/molcells.2017.0051

• 
  


• 
  

StephenW

分子细胞。 2017年6月14日。doi：10.14348 / molcells.2017.0051。 [提前印刷]
艾滋病病毒治疗慢性HBV感染患者IP-10表达及其预测HBsAg水平降低的能力。
赵K1,2，杨T3,2，孙M4，张W4，安Y4，陈G4，金L3，尚Q4，宋W1。
作者信息

1
泰山医科大学免疫学研究所，泰安271000。
2
作者的作者贡献了这项工作。
3
北京302医院转化肝病研究所生物治疗研究中心，北京100039。
4
>解放军第88医院肝病系，泰安271000。

抽象

也称为趋化因子CXC基因配体（CXCL）10的干扰素-γ诱导蛋白10（IP-10）与抗病毒免疫和慢性乙型肝炎（CHB）的进展密切相关。然而，在预测抗病毒反应对核苷/核苷酸类似物（NAs）的功效的准确血清学和组织学IP-10表达水平的价值尚不清楚。在我们的研究中，使用恩替卡韦（ETV）治疗前后，对肝内和外周IP-10表达水平进行系统检查。 CHB患者的基线血清学和组织学IP-10表达水平显着升高，特别是肝脏炎症和肝纤维化程度较高的患者。此外，恩替卡韦治疗后，CHB患者肝内IP-10水平的更高基线更好预后。基线IP-10水平也与几个临床参数相关，包括丙氨酸氨基转移天冬氨酸（ALT），天冬氨酸氨基转移酶（AST），乙型肝炎病毒（HBV）DNA和乙型肝炎表面抗原（HBsAg）的基线水平，以及治疗后HBsAg水平降低。此外，单核细胞衍生的IP-10在CHB患者中的表达水平低于肝硬化患者（LC）和健康对照（HC）患者。根据我们的体外实验的结果，IP-10其中恩替卡韦治疗后，-10水平可能预示CHB严重程度和HBsAg水平的降低。

结论：
28614914
DOI：
10.14348 / molcells.2017.0051